DEVELOPMENT AND OPTIMIZATION OF RIZATRIPTAN BENZOATE ETHOSOMES

MILIND P. WAGH1;, SWATI S. MUTHA BORA1,b
1Department of Pharmaceutics, MVP Samaj's College of Pharmacy, Nashik, India; bDepartment of Pharmaceutics, S. G. R. S. College of Pharmacy, Saswad, Pune, India
Email: swati.mutha@rediffmail.com

Received: 19 Dec 2017, Revised and Accepted: 13 Feb 2018

INTRODUCTION

RBZ is a potent and selective serotonin (5-HT1B/1D) receptor, agonist. It is a second-generation Triptan and used in the acute treatment of migraine attacks with or without aura and cluster headaches [1–3]. RBZ is available in the market as tablet and wafer form [4]. A migraine many times associated with nausea, vomiting and gastric stasis which make oral route unsuitable. It is also reported that the oral bioavailability of RBZ is only 45% due to hepatic first pass effect and half-life is 2-3 h, so require frequent administration [5]. As an episodic condition of a migraine, later on, may become chronic, therefore need to develop a sustained release dosage form as alternate route of administration. Recently it was investigated that topical administration of triptans may increase clinical efficacy by avoiding the first-pass effect of the liver, avoiding discomfort and risks of an intravenous treatment, avoiding side effects in the region of the gastrointestinal tract in the case of oral medication, and good patient acceptance. Absorption peaks involving the risk of systemic side effects may also be avoided [6]. In the literature, topical/transdermal delivery of RBZ has been suggested to be beneficial by different authors [5, 7–9]. Recently As per European patent No 1435945 a concept of topical regional neuroaffetive (TRNA) therapy in which action of triptan at peripheral neural synapse take place after topical application at posterior cervical region i.e back of the ear, preferably in close proximity to or on the area of skin above the brain stem had been proposed [6]. In TRNA therapy drug need only transverse the stratum corneum of the skin to reach cutaneous free nerve endings for therapeutic effect. This alternate route of administration will promote drug localization at peripheral neural synapse containing neurotransmitter release like CGRP and will also be avoided cardiac side effects associated with RBZ [10]. The main obstacle of crossing stratum corneum (SC) can be overcome by using flexible vesicular drug delivery system like ethosome [11–13]. These vesicular systems have the capacity to load both lipophilic as well as the hydrophilic drug. Unlike other vesicular systems, ethosomes can better encapsulate hydrophilic moieties [14]. The aim of this study was to assess the applicability of ethosomal drug delivery system for sustained and site specific delivery of RBZ through the topical application to cranial skin.

MATERIALS AND METHODS

Materials

Rizatriptan benzoate was obtained as a gift sample from Cipla Ltd, Kurkumbh, sacyophosphatey choline (SPC) (Sigma Chemicals) were used. Demineralize and double distilled water were used. Carbopat® 934 (SD Fines Chemical Ltd, Mumbai), ethanol absolute, propylene glycol (Merck, Mumbai). All other chemicals were of HPLC grade and used without further modification.

Analytical method

RBZ was analysed for percent entrapment efficiency (%EE), percent cumulative drug release (% CDR) and percent diffusion study by UV double beam spectrophotometer (Shimadzu-1800, Japan) in phosphate buffer pH 6.8 by generating a standard curve for the range from 0 to 5 µg/ml at 225 nm [5].

Preparation of ethosomes

Ethosomes were prepared by the cold method, as reported and described earlier [12, 16, 17]. Briefly, in a completely dried glass vial, SPC was dissolved in ethanol by vigorous stirring. Propylene glycol is added in ethanol solution. The glass vial was sealed up completely and connected with a tube to a syringe system to allow the addition of water and to avoid ethanol evaporation as far as possible. This mixture was heated to 30 °C in a water bath. RBZ was dissolved in phosphate buffer pH 6.8. The aqueous mixture was heated to 30 °C in a separate vessel. Then it was added to the ethanolic mixture dropwise in the centre of the vessel. Mixing was continued for an additional 15 min at 700 rpm in a covered vessel. Ethosomes were formed spontaneously by this process.
Experimental design

A 3\(^3\) full factorial design was utilized in the present study. Several studies revealed that the optimized lipid concentration, ethanol concentration and stirring speed plays a notable role in lamellar configuration, on entrapment of the drug and stability of the dispersion system [11, 18–20]. Here an attempt was made to study the interactive effect of all these variables on ethosome formulation characteristics. The design layout and coded value of independent factor are shown in table 1. The lipid concentration, ethanol concentration and stirring speed were selected as independent variables. The vesicle size, % EE and visual stability of dispersion for one week were selected as dependent variables. Minitab 17 trial version was used for the generation and evaluation of the statistical experimental design. An ANOVA test was performed to evaluate the level of significance of the tested factors on the selected responses as well as the interactions between these factors. Application of regression analysis is important to check that our independent variables have a significant effect on our response or not. Surface response plots were also presented to graphically represent the effect of the independent variables on the vesicle size and percentage entrapment efficiency.

| Table 1: Composition of different coded values in 3\(^3\) full (general) factorial design of RBZ ethosomes |
|----------|-----------------|-----------------|-----------------|
| Coded Values | X\(_1\): A [SPC concentration (%)] | X\(_2\): B [ethanol concentration (%)] | X\(_3\): C [stirring speed (Rpm)] |
| Levels | Low (1) | Medium (2) | High (3) |
| X\(_1\) | 2 | 3 | 4 |
| X\(_2\) | 35 | 40 | 45 |
| X\(_3\) | 700 | 800 | 900 |

Microscopy

All batches of the ethosomes prepared were viewed under a digital microscope with camera attachment having software to study their size, shape and aggregation property. The ethosomal dispersion was suitably diluted and put on a glass slide and viewed with a binocular microscope with a magnification of 10X.

\% EE

Ethosomal suspensions were ultra-centrifuged at 14,000 rpm and 4 °C for 90 min. After centrifugation, 1 ml of supernatant was diluted with the addition of 9 ml phosphate buffer (pH 6.8) and then the absorbance was measured using UV-Vis spectrophotometer by measuring absorbance at 225 nm. The drug entrapment efficiency was calculated as below,

\[ \text{% EE} = \frac{\text{WT} - \text{WF}}{\text{WT}} \times 100\% \]

where % EE is the percent entrapment efficiency of the drug. WT is the total amount of RBZ in ethosomal suspension, WF is the free amount of RBZ that was in the supernatants [21].

Visual stability

Ethosome dispersion stability was observed visually after storing it at 4 °C for a week. Presence of layer formation, aggregates is indicated stability issue.

Statistical analysis

Different polynomial equations for different models were generated by using the multiple regression analysis in 3\(^3\) factorial design with the interacting term and regression coefficient for evaluating the responses. The responses were analysed using the quadratic equation. Statistical analysis was carried out using Minitab 17 trial version. The difference is considered statistically significant using ANOVA when p < 0.05.

Characterization and evaluation of optimized formulation

SEM

Morphology of ethosomes was studied using SEM of the optimized ethosomal formulation was performed for determining the surface morphology, size and shape of the formulation and observing the aggregation property of ethosomes. Selected ethosomal formulation was examined by SEM at different magnification powers at 10 KV.

Vesicle size distribution and surface charge

The vesicle size and size distribution of ethosomes were determined by Malvern Zetasizer based on laser light scattering principle. Light scattering was monitored at 90 ° angle and at 25 °C. The mean vesicle size was calculated from the intensity, volume and bimodal distribution assuming spherical particles. The zeta potential is an indication of the stability of the colloidal systems and indicates charge present in colloidal systems. Zeta potential of optimized formulations was determined using Malvern Zetasizer. Samples were placed in clear disposable zeta cells and results were recorded.

Stability evaluation

The RBZ-loaded F4E459 dispersions were stored in a sealed glass vial and subjected to physical stability study in triplicate. The vials were kept at two different storage conditions, i.e., 4±2 °C with ambient humidity and room temperature 25±2 °C, and the samples were withdrawn periodically at an interval of one month for 3 months, suitably diluted with water and analysed for percent encapsulation efficiency. Samples were also observed for uniformity of dispersion.

Preparation of gels

Gel base was prepared by dispersing 1% w/v Carbopol 9403 in distilled water. The polymer was soaked in water for 2 h and then dispersed in distilled water using a magnetic stirrer so as to obtain a homogeneous gel adjusting the pH by using triethanolamine solution [22]. For preparation of ethosomal gel, the ethosomal suspension(s) was centrifuged at 14000 rpm for 20 min, and the pellets obtained were incorporated into the prepared gel base to get 5 mg RBZ per gram.

In vitro skin permeation studies

Albino rats of Wistar strain of either sex between 200-210 g breed were selected and maintained as per CPCSEA guidelines for the studies. They were fed with standard rodent pelleted chow and water. Light and dark cycle with 12 h light and 12 h dark was maintained. The temperature and relative humidity conditions were 25 ±2 °C and 60±10 % respectively. The experiments were performed as per the protocol approved by CPCSEA (CPCSEA: Letter No. SGRS/IACUC/8/2014-15). The animals were fasting overnight but allow water at libitum Hairs from the abdominal side of albino rats was removed by shaving after anaesthetized with ketamine injection. The animals were sacrificed. Abdomen skin was carefully excised. After removing the hypodermal adipose tissue the skin was used as a barrier membrane for the studies. The in vitro skin permeation of RBZ from optimized ethosomal solution and gel prepared with optimized formulation, in comparison with plain drug solution were studied using Franz glass diffusion cell maintained at 32±1 °C under non-occlusive conditions using albino abdomen rat skin. The effective permeation area of the diffusion cell was 2.303 cm\(^2\). The receptor compartment contained 48.00 ml phosphate buffer (pH, 6.8) and was constantly stirred at100 rpm. Excised albino abdomen rat skin was mounted between the donor and the receptor compartment. Ethosomal formulation (1.0 ml) was applied to the epidermal surface of the skin. The samples (1 ml) were withdrawn through the sampling port of the diffusion cell at 1-, 2-, 4-, 6-, and 8-h time intervals and analysed. An equal volume of fresh phosphate buffer maintained at 32±1 °C was replaced into the receptor compartment after each sampling. The samples were filtered through 0.45 μm nylon filter membrane and analysed using spectrophotometer for drug content at
225 nm. The cumulative amount of drug permeated per unit area was plotted as a function of time.

Release kinetic studies–release pattern and mechanism

Data of in vitro RBZ release from ethosomal solution and gel were evaluated kinetically using various mathematical models like zero-order, first-order, Higuchi and Koresmeyer–Peppas model equations to describe release patterns and mechanisms. Model-dependent methods all rely upon a curve fitting procedure.

Skin irritancy studies

The skin irritancy (erythema) potential of the ethosomal gel was evaluated. Guidelines of the institutional animal ethics committee were followed for this experiment. Hair on the dorsal side of Wistar albino rats was removed by clipping 1 d before the experiment. The rats were allocated into 3 groups (n = 3). Group I served as the control (saline solution). Group II received optimized ethosomal gel and group III received a 0.8% v/v aqueous solution of formalin as a standard irritant. The 0.5 g of each test product was placed on each area (25 × 25 mm), reactions on the skin were measured for 24 h and 72 h in the form of erythema. The mean erythema scores were recorded (ranging from 0 to 4) according to Draize scale as no erythema–0, very slight erythema (barely perceptible-light pink)–1, well-defined erythema (dark pink)–2, moderate to severe erythema (light red)–3, severe erythema (dark red)–4 [23].

Transmission electron microscopy (TEM)

Selected ethosomal gel was examined by transmission electron microscopy at different magnification power at 80 K V using transmission electron microscope model JEM@100S (Joel@Japan).

RESULTS AND DISCUSSION

Ethosome formation

Ethosomes were spontaneously produced by dissolution of SPC in ethanol along with propylene glycol followed by slow addition of an aqueous buffer under continuous stirring at 30 °C (fig. 1). During preparation, dispersions displayed initial optical transparency due to the high ethanol concentration which may maintain SPC in solution. By adding increasing concentrations of phosphate buffer, dispersions became turbid. The turbidity of the system is ascribed to a reorganization of SPC molecules within the system, resulting in ethosomal vesicles formation. Propylene glycol used in formulation widely used as a penetration enhancer in a topical formulation, either alone or in combination with other fatty acids. It will enhance solubility and partitioning of the drug in SC, and increase the flux and permeation across SC.

Analysis of factorial design

Preliminary formulation screening data was utilized for defining design space in 3° full factorial designs shown in table 1 for an optimization study. Average vesicular size and percent entrainment efficiency were selected as response parameters, as they play a decisive role in providing topical efficacy of the formulation. Visually evaluated formulation stability as constraining factor was used for selection of optimized stable formulation. Varying phospholipid (2 %, 3 % and 4 % w/v), ethanol concentration (35 %, 40 % and 45 %w/v) and stirring speed (700, 800 and 900 RPM) led to a change in mean vesicular size ranging from 3.5 to 9.0 µm (under 10X magnification) and % EE from 68.12 % to 93.32 % (table 2).

The ANOVA study (table 3) of the model relating vesicle size as a response is found that no interaction factors are significant (P ≥ 0.05). A multiple regression model fitting for vesicular size response was carried out to obtain a first-order polynomial equation by excluding the terms for which the level of significance was greater than 0.05, as expressed in equation 1:

\[
\text{Vesicle Size} = 9.000 + 0.611 A - 1.333 B - 0.667 C
\]

This equation revealed that lipid concentration has a positive effect while ethanol concentration and stirring speed both have a negative effect on vesicle size. Ethanol concentration was found to be the dominant factor as per Eqn 1. Ethanol significantly reduces vesicle membrane thickness, probably as a result of the interpenetration of the hydrocarbon chain in the vesicular lipid bilayers [24]. Furthermore, ethanol imparts a net negative charge to the ethosomal system and confers it some degree of steric stabilization that may finally lead to a reduction in vesicular size [12, 25]. The influences of factors on response Y1 here vesicle size are further supported by a surface plot study as showed in fig. 2 a, b and c.

Table 2: Full factorial design matrix of RBZ ethosomes with evaluation parameters

| Formulation code | X1: A | X2: B | X3: C | Y1: (VS) (µm) | Y2: (%EE) | Stability by visual means |
|------------------|------|------|------|-------------|---------|-------------------------|
| F2E459           | 2    | 45   | 900  | 3.52        | 78.36   | Stable                  |
| F2E409           | 2    | 40   | 900  | 5.06        | 74.74   | Stable                  |
| F2E359           | 2    | 35   | 900  | 6.13        | 71.62   | Stable                  |
| F2E458           | 2    | 45   | 800  | 4.25        | 76.41   | Stable                  |
| F2E408           | 2    | 40   | 800  | 5.54        | 72.84   | Stable                  |
| F2E358           | 2    | 35   | 800  | 7.24        | 70.54   | Stable                  |
| F2E457           | 2    | 45   | 700  | 5.21        | 73.43   | Stable                  |
| F2E407           | 2    | 40   | 700  | 6.58        | 69.91   | Stable                  |
| F2E357           | 2    | 35   | 700  | 7.56        | 68.12   | Stable                  |
| F3E459           | 3    | 45   | 900  | 4.51        | 84.69   | Stable                  |
| F3E409           | 3    | 40   | 900  | 6.04        | 78.92   | Stable                  |
| F3E359           | 3    | 35   | 900  | 7.22        | 76.53   | Stable                  |
| F3E458           | 3    | 45   | 800  | 5.42        | 79.21   | Stable                  |
| F3E408           | 3    | 40   | 800  | 7.36        | 75.03   | Stable                  |
| F3E358           | 3    | 35   | 800  | 8.15        | 72.68   | Stable                  |
| F3E457           | 3    | 45   | 700  | 6.01        | 75.81   | Stable                  |
| F3E407           | 3    | 40   | 700  | 7.51        | 72.45   | Stable                  |
| F3E357           | 3    | 35   | 700  | 8.54        | 70.25   | Not stable              |
| F4E459           | 4    | 45   | 900  | 5.48        | 93.32   | Stable                  |
| F4E409           | 4    | 40   | 900  | 7.26        | 91.80   | Stable                  |
| F4E359           | 4    | 35   | 900  | 8.12        | 84.61   | Not stable              |
| F4E458           | 4    | 45   | 800  | 6.34        | 92.12   | Stable                  |
| F4E408           | 4    | 40   | 800  | 7.47        | 90.51   | Not stable              |
| F4E358           | 4    | 35   | 800  | 8.53        | 81.36   | Not stable              |
| F4E457           | 4    | 45   | 700  | 7.51        | 91.23   | Stable                  |
| F4E407           | 4    | 40   | 700  | 8.09        | 89.75   | Not stable              |
| F4E357           | 4    | 35   | 700  | 8.45        | 76.32   | Not stable              |

Formulation code denotes from left to right as F-formulation, 1st digit–SPC concentration (%), E-ethanol, next two digit ethanol concentration (%), last digit denotes speed of stirring in hundreds, X indicates independent variable and Y indicates dependent variable, A: SPC concentration (%), B: Ethanol concentration (%), C: stirring speed (Rpm), Y1: vesicle average size, Y2: Percent entrainment efficiency.
Fig. 1: Microscopic image of ethosomes with 10X magnification

Table 3: Results of ANOVA for the response parameter–vesicle size

| Source | Sum of squares | DF | Mean square | F-Value | P-Value |
|--------|----------------|----|-------------|---------|---------|
| Model  | 54.5972        | 6  | 9.09954     | 115.96  | 0.000   |
| A      | 0.51709        | 1  | 0.51709     | 6.59    | 0.018   |
| B      | 2.4615         | 1  | 2.46154     | 31.37   | 0.000   |
| C      | 0.6154         | 1  | 0.61538     | 7.84    | 0.011   |
| A*B    | 0.1875         | 1  | 0.18750     | 2.39    | 0.138   |
| A*C    | 0.0208         | 1  | 0.02083     | 0.27    | 0.612   |
| B*C    | 0.0833         | 1  | 0.08333     | 1.06    | 0.315   |

A, B and C = main factors; A*B, A*C, and B*C = interactions between main factors; DF = degree of freedom

The F-value of 31.92 observed with ANOVA data of the model for percent entrapment efficiency as a response (table 4), indicated that the model is significant and all the independent variables, as well as AB interaction factor, are found to have a significant effect on the response (P ≤ 0.005).

Fig. 2: Surface plot of vesicle size, a. Vesicle size VS stirring speed (RPM), SPC concentration (%), b. Vesicle size VS stirring speed (RPM), ethanol concentration (%), c. Vesicle size VS ethanol concentration (%), SPC concentration (%)

Fig. 3: Surface plot of percent entrapment efficiency, a. Surface plot of % EE VS ethanol concentration (%), SPC concentration (%), b. Surface plot of % EE VS ethanol concentration (%), stirring speed–RPM, c. Surface plot of % EE VS stirring speed–RPM, SPC concentration(%)
The final regression model equation obtained was expressed in equation 2:

\[ \% \text{EE} = 55.68 + 5.02A + 2.688C + 1.61B + 1.128A \times B \]

Where it can be noticed that all the main factor have a positive influence on \% EE, among this lipid concentration had a more prominent effect. The influences of the main effects (factors) on responses (here, \% EE) were further elucidated by the surface plot as showed in fig. 3 a, b, and c. Alcohol concentration and SPC concentration found to influence the stability of the formulation. The 2 \% w/v of SPC concentration gave all stable formulation irrespective of the variations in ethanol concentration and stirring speed. At 4 \% w/v of SPC along with 35 \% v/v alcohol showed the problem of stability irrespective of stirring speed. Higher concentration of alcohol was found to impart stability to formulations having 4 \% w/v of SPC.

The optimum values of the variables are obtained by graphical and numerical based on the criterion of desirability using the prediction and optimization report as per fig. 4 by using Minitab.

The vesicle size and entrapment efficiency of the vesicular carrier are the parameters mostly influence the permeation of entrapped drug through the skin. For this reason, formulation F4E459 (4 \% SPC, 45 \% v/v ethanol 900 RPM), which is characterized by optimum vesicle size (5.5 \(\mu\)m) and high entrapment efficiency (93.32 \%) was considered to be an optimal formulation and carried forward for further investigations.

### Table 4: Results of ANOVA for the response parameter–\%EE

| Source | Sum of square | DF | Mean square | F-Value | P-Value |
|--------|--------------|----|-------------|---------|---------|
| Model  | 1711.32      | 18 | 95.073      | 31.92   | 0.007   |
| A      | 1349.61      | 2  | 674.804     | 226.58  | 0.000   |
| B      | 190.52       | 2  | 95.260      | 31.99   | 0.000   |
| C      | 110.59       | 2  | 55.297      | 18.57   | 0.018   |
| A*B    | 14.41        | 4  | 3.602       | 1.21    | 0.048   |
| A*C    | 30.56        | 4  | 7.640       | 2.57    | 0.120   |
| B*C    | 15.63        | 4  | 3.906       | 1.31    | 0.344   |

Evaluation of optimized formulation

Ethosome system F4E459 was selected for further studies, as it offered the best compromise in characteristics: mean vesicle size, drug entrapment efficiency percentage and stability.

SEM study

It is seen from SEM photomicrograph fig. 5 that optimized ethosome vesicles are unilamellar, nano ranged with a smooth surface and showing some deviation in terms of spherical shape explaining the fluidizing effect of ethanol, a phenomenon observed earlier [16].

Vesicle size distribution and surface charge

The polydispersity index (PI) was determined as a measure of homogeneity of the formulation [11]. Dynamic Light Scattering (DLS) revealed small PI of the optimized formulation as 0.493±0.021 (fig. 6) and the average vesicle diameter range of optimized ethosomal suspension was 226±7.42 nm. A small value of PI (<0.5) indicates a homogenous population of ethosome vesicles. The negative zeta potential values (≤-15mV) was indicative of a good stability against vesicle aggregation and fusion [26]. The zeta potential of that ethosomal suspension was -21.3 mV which is sufficient to inhibit aggregation of ethosomes due to electric repulsion (fig. 7). This negative charge value of ethosomes is attributed to the presence of ethanol.

Fig. 5: SEM photograph
Stability evaluation study

Physical stability study of the optimized ethosome formulation was conducted at refrigeration temperature [4±2 °C] and at room temperature [25±2 °C] for a period of 3 mo. No significant changes in drug entrapment efficiency, as well as no signs of separation or change in colour, were observed for the formulation stored at refrigerated temperature. Low entrapment efficiency of ethosomes with marked separation and slight yellow discoloration was observed when stored at room temperature (table 5) as at room temperature ethosomes became unstable due to oxidation and become aggregated which led to leakage of the drug. The percent RBZ retained by ethosomal formulations after 90 d were 86.95±1.52 % and 55.36±1.03 % when stored at refrigerated and room temperature respectively. These results were in agreement with what has been previously recommended that ethosomal suspensions should be kept refrigerated to achieve the best stability [27].

### Table 5: Stability study of RBZ ethosomes at different storage conditions

| Time (mo) | Physical stability of dispersion | %EE*          |
|----------|---------------------------------|---------------|
| 0        | Uniform dispersion              | Storage at 4 °C 92.2±1.23 | Storage at 25 °C 92.2±1.23 |
| 1        | Uniform dispersion              | Storage at 4 °C 91.5±0.94 | Storage at 25 °C 81.5±2.30 |
| 2        | Uniform dispersion              | Layer formation 88.1±0.32 | Layer formation 69.6±1.25 |
| 3        | Uniform dispersion              | Layer formation 86.9±1.52 | Layer formation 55.3±1.03 |

* SD standard deviation from mean, n=3

**In vitro skin permeation studies**

The investigation of efficient prolong release ability of ethosomal formulation was done by Franz diffusion cell measurement using the abdominal portion of a rat. The percent cumulative amount of RBZ permeated across excised rat skin over 8 h periods was plotted against the function of time (fig. 8) and lag time was determined. From the release profiles it was observed that after 3.5 h, the maximum drug was permeated from the drug solution (99.1±5.1 %), this explains the need for prolonging release formulation development. Optimized Ethosomal RBZ solution show a significant reduction in vitro drug release (p<0.001) in 3.5 h compared with the drug in solution. The release profile of RBZ from ethosome solution was biphasic. Initial rapid release up to 2 h which could probably be...
due to the portion of the drug that leaked out of ethosome and the unloaded drug followed by extended-release up to 8 h with around percent cumulative release of around 89% was observed. The very low viscosity often exhibited by ethosome is not suitable for topical use. The viscosity can be increased by adding thickening agents, which also change the appearance of the system, usually influencing drug release. As a vehicle for incorporation of ethosomes for skin delivery, the ethosome formulation was loaded in 1% Carbopol 934.\(^{[28]}\) Among the various hydrogel bases, Carbopol is used because of its high stability, compatibility and low toxicity.\(^{[29]}\) \textit{In vitro} release data of ethosomal gel revealed around 81% release of RBZ in 8 h in which around 26% release within 1 h which assumes to be sufficient as a loading dose. This bi-phasic pattern release is a characteristic feature of matrix diffusion kinetics. The ethosomal gel formulation showed controlled drug release due to the entrapment of drug in vesicles. Permeation study suggested that the gelling agent in the concentration used had little effect on drug release and that the rate-limiting step was the diffusion of the drug out of the ethosomes.

![Fig. 8: Percent cumulative amount of \textit{in vitro} RBZ permeated through rat skin vs. time profile of RBZ solution, • RBZ optimized ethosome solution □ and gel △, (mean±SD, n = 3)](image)

**Release kinetic studies**

The results of the curve fitting into for mathematical models of release kinetics after comparing the respective correlation coefficients indicate the \textit{in vitro} RBZ permeation behaviour of the ethosomal solution and gel (table 6) were followed by the Higuchi model. The 'n' values for a solution and gel formulation were found to be 0.664 and 0.693 respectively which are more than 0.5. This indicates that the release approximates non-Fickian diffusion mechanism.\(^{[30]}\) and the gel was selected for next skin irritation studies.

| Formulation       | Zero-order | First order | Higuchi | Korsemeyer-Peppas |
|-------------------|------------|-------------|---------|-------------------|
| Ethosome sol      | 0.9746     | 0.8114      | 0.9854  | 0.664             |
| Ethosome gel      | 0.9493     | 0.7523      | 0.9892  | 0.693             |

**Table 6: Kinetic models of formulation**

**Skin Irritation test**

We conducted the skin irritancy studies of the ethosomal gel formulation. Measurement of erythema scores upon exposure of hairless rat skin to various formulations including saline solution (0.9% w/v NaCl solution, negative control), ethosomal gel formulation, and Formalin solution (0.8% v/v, positive control) as per table 7 revealed that saline and ethosomal gel showed no significant erythema, whereas remarkable skin erythema was observed with formalin solution, demonstrating that ethanol present in the ethosomal formulation is not able to act as a skin erythema inducing agent, even though present in high concentration. Irritation score (primary skin irritation index) of RBZ ethosomal gel was zero, which indicated its safety and acceptability for topical administration.

**Table 7: Skin irritation test**

| Groups   | Saline solution | RBZ ethosomal gel | Formalin solution |
|----------|-----------------|-------------------|-------------------|
|          | Erythema score  | Erythema score    | Erythema score    |
|          | 24 h 72 h       | 24 h 72 h         | 24 h 72 h         |
| Animal 1 | 0 0             | 0 0               | 2 2               |
| Animal 2 | 0 0             | 0 1               | 3 3               |
| Animal 3 | 0 0             | 0 0               | 3 2               |
| Primary irritation index (PII) | 0/6 = 0 | 1/6 = 0 | 15/6 = 2.5 |
| No irritation | Negligible irritation | Moderate irritation |

![Fig. 9: The transmission electron microscopic image of optimized ethosomal gel formulation](image)
Transmission electron microscopy

It is seen from TEM photomicrograph that ethosomal vesicles are unilamellar in nature with nearly spherical shape (fig 9) and also depict the absence of aggregates. However, optimized ethosomal gel TEM photomicrograph also revealed that vesicles remain intact after dispersion into gel formulation.

CONCLUSION

The study revealed the development of ethosomal carrier as suitable drug delivery system for RBZ considering the site-specific topical approach. 3 full factorial designs were prepared and evaluated to study composition and processing factors influencing the formulation of ethosomes. The study demonstrated that all factors had a positive impact and interaction effect of lipid concentration and ethanol also found to be significant on % EE. The ethosome formulation was optimized for maximum entrapment efficiency and RBZ ethosomal gel of optimized formulation was prepared and evaluated successfully for an in vitro permeation across the rat abdomen skin. It can be concluded that the ethosomal gel prepared with Carbopil 934P can be used without skin irritation and can release RBZ for 8h.

ACKNOWLEDGEMENT

The authors are grateful to M/s Cipla Ltd. India, for providing RBZ as a gift sample. The acknowledgement also goes to Dr. V.R. Undale (India) for her expert support for the animal study.

AUTHORS CONTRIBUTIONS

All the authors have contributed equally

CONFLICTS OF INTERESTS

Declare none

REFERENCES

1. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against dually evoked responses. Eur J Pharmacol 1997;328:37–40.
2. Lee Y, Conroy JA, Stupanavage ME, Mendel CM, Somers G, Mcloughlin DA, et al. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br J Clin Pharmacol 1999;47:373–81.
3. Ramadan NM, Buchanan TM. New and future migraine therapy. Pharmacol Ther 2006;12:199–212.
4. Fontebasso M. Current treatment options in the management of a migraine. Prescriber 2008;19:42–58.
5. Lahoti SR, Taur NG, Khan AR, Puranik PK. Enhanced iontophoretic permeation of rizatriptan benzoate from the thermo-reversible gel based system: effect of penetration enhancers and pulsed current. Indian J Pharm Educ Res 2012;46:105–11.
6. Aung-din R. European patent 1 345 945 b1. 2008;1:1–17.
7. Sharma A, Thway AK. Elastic liposomal formulation for sustained delivery of antimigraine drug: in vitro characterization and biological evaluation. Drug Dev Ind Pharm 2008;34:1100–10.
8. Aung-din R. United States Patent; 2012. p. 2.
9. Femenía Font A, Balaguer Fernández C, Merino V, Lopez Castellano A. Iontophoretic transdermal delivery of sumatriptan: effect of current density and ionic strength. J Pharm Sci 2005;94:2183–6.
10. Aung Din R. United States Patent; 2012. p. 2.
11. Dubey V, Mishra D, Jain NK. Melatonin loaded ethanolic liposomes: Physicochemical characterization and enhanced transdermal delivery. Eur J Pharm Biopharm 2007;67:398–405.